Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Has Consensus Target Price of $6.00 According to Analysts

Posted by Brenda Bartman on Nov 5th, 2026

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) have received an average recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.00.

A number of equities research analysts have issued reports on CTXR shares. HC Wainwright restated a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th. Citigroup reiterated a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday, September 21st.

Read Our Latest Analysis on Citius Pharmaceuticals

Institutional Trading of Citius Pharmaceuticals

An institutional investor recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. purchased a new position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned about 0.25% of Citius Pharmaceuticals at the end of the most recent reporting period. 16.88% of the stock is owned by institutional investors and hedge funds.

Citius Pharmaceuticals Trading Down 3.9%

Shares of Citius Pharmaceuticals stock opened at $0.55 on Monday. The company’s 50 day moving average is $0.53 and its 200 day moving average is $0.65. Citius Pharmaceuticals has a twelve month low of $0.37 and a twelve month high of $1.54. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.40 and a current ratio of 0.84.

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.02. Research analysts predict that Citius Pharmaceuticals will post -2.03 EPS for the current fiscal year.

About Citius Pharmaceuticals

(Get Free Report)

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market.

Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place.